SpringerProtocols: Abstract: Purification of Clostridium botulinum Type A Neurotoxin

Purification of Clostridium botulinum Type A Neurotoxin

By: Carl J. Malizio², Michael C. Goodnough², Eric A. Johnson²

Abstract

Full Text

Download PDF (245K)

Botulinum neurotoxins produced by strains of the spore-bearing bacterium Clostridium botulinum have long been known to cause a distinctive paralytic disease in humans and animals (1). In recent years, injection of crystalline botulinum toxin type A has been demonstrated to provide relief from certain involuntary muscle disorders, dystonic conditions, pain syndromes, and headaches (2,3,4). The use of botulinum toxin for treatment of human disease and its usefulness in cell biology (5) has stimulated interest in the study of the toxin complexes and the neurotoxin component within the complexes. The use of botulinum toxin complex in medicine will benefit from the development of more potent, less antigenic, and longer-lasting toxin preparations. In this chapter we describe methods for production of high-quality botulinum type A toxin complex and neurotoxin. The procedures described in this chapter are not those used for preparation of botulinum toxin for medical use (3).

Affiliation(s): (2) Department of Food Microbiology and Toxicology, University of Wisconsin, Madison, WI

Book Title: Bacterial Toxins: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 145 | Pub. Date: Mar-10-2000 | Page Range: 27-39 | DOI: 10.1385/1-59259-052-7:27

Subject: Infectious Diseases

References

Download References

1.	Smith L. D. S., and Sugiyama H. (1988) Botulism, 2nd ed., Charles C. Thomas Springfield, IL.

2.	Schantz E. J. and Johnson E. A. (1997) Botulinum toxin: the story of its development for the treatment of human disease. Perspect. Biol. Med. 40, 317–327.

3.	Schantz E. J. and Johnson E. A. (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 56, 80–99.

4.	Jankovic J. and Hallett M., eds. (1994) Therapy with Botulism Toxin, Marcel Dekker New York, NY.

5.	Montecucco C., ed. (1995) Clostridial Neurotoxins, Springer-Verlag Berlin.

6.	Lamanna C. (1959) The most poisonous poison, Science 130, 763–772.

7.	Centers for Disease Control and Prevention (1998) Laboratory Registration and Select Agent Transfer Tracking System, 42 CFR 72, U.S. Dept. of Health and Human Services Washington, D. C.

8.	Centers for Disease Control and Prevention/National Institutes of Health (1999) Biosafety in Microbial and Biomedical Laboratories. 4th ed. U.S. Dept. of Health and Human Services, pp. 94–95.

9.	Schantz E. and Johnson E. A. (1993) Quality of botulinum toxin for human treatment, in Botulinum and Tetanus Neurotoxins (DasGupta B. R., ed.), Plenum New York, pp. 657–659.

10.	Sugiyama H. (1980) Clostridium botulinumneurotoxin. Microbiol. Rev. 44, 419–448.

11.	Schantz E. and Scott A. (1981) Use of crystalline type A botulinum toxin in medical research, in Biomedical Aspects of Botulism(Lewis G. E., ed.), Academic Press San Diego, CA, pp. 143–150.

12.	Lamanna C. McElroy O. E., and Eklund H. W. (1946) The purification and crystallization of Clostridium botulinum type A toxin. Science 103, 613.

13.	Duff J., Wright G., Klerer J., Moore D., and Bibler R. (1957) Studies on immunity to toxins of Clostridium botulinum. I. A simplified procedure for isolation of type A toxin. J. Bacteriol. 73, 42–47.

14.	Sugiyama H., Moberg L., and Messer S. (1976) Improved procedure for crystallization of Clostridium botulinum type A toxic complex. Appl. Environ. Microbiol. 33, 963–966.

15.	DasGupta B. and Boroff D. A. (1967) Chromatographic isolation of hemagglutinin-free neurotoxin from crystalline toxin of Clostridium botulinum type A. Biochim. Biophys. Acta 147, 603.

16.	Tse C., Dolly J., Hambleton P., Wray D., and Melling J. (1982) Preparation and characterization of homogeneous neurotoxin type A from Clostridium botulinum. Eur. J. Biochem. 122, 493–500.

17.	DasGupta B. and Sathyamoorthy V. (1984) Purification and amino acid composition of type A botulinum neurotoxin. Toxicon 22, 415–424. <Occurrence Type="DOI"><Handle>10.1016/0041-0101(84)90085-0</Handle></Occurrence>

18.	Moberg L. and Sugiyama H. (1978) Affinity chromatography purification of type A botulinum neurotoxin from crystalline toxic complex. Appl. Environ. Microbiol. 35, 878–880.

19.	Boroff D. and Fleck U. (1966) Statistical analysis of a rapid in vivo method for the titration of the toxin of Clostridium botulinum. J. Bacteriol. 92, 1580–1581.

20.	Kondo H., Shimizu T., Kubonoya M., Izumi N., Takahashi M., and Sakaguchi G. (1984) Titration of botulinum toxins for lethal toxicity by intravenous injection into mice. Jpn. J. Med. Sci. Biol. 37, 131–135.

21.	Schantz E. and Kautter D. (1978) Standardized assay for Clostridium botulinum toxins. J. Assoc. Off. Anal. Chem. 61, 96–99.

22.	Pearce L., Borodic G., First E., and MacCallum R. (1994) Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol. Appl. Pharmacol. 128, 69–77.

23.	Lin W.-J. and Johnson E. A. (1996) Genome analysis of Clostridium botulinum type A by pulsed-field gel electrophoresis. Appl. Environ. Microbiol. 61, 4441–4447.

Comments (Loading...)

Post comment/View all comments